Skyhawk Secures $8M in Seed Funding to Advance Small Molecule Therapies Targeting RNA
Skyhawk Therapeutics, focused on the discovery and development of small molecule therapeutics that correct RNA expression, has announced the close of $8 million in seed funding led by major family and biotech investors.